RUNX2

Across TCGA pan-cancer cohorts, RUNX2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RUNX2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where RUNX2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RUNX2 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

PDAC, LUAD, and CCRCC are the cancer types where RUNX2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RUNX2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	+0.593	<.001	5	view →
LUAD	All	All	−0.141	.010	2	view →
CCRCC	All	IV	+0.925	.011	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RUNX2–PDAC

Open the PDAC breakdown →